Patent · US Active

Combination therapies targeting PD-1, TIM-3, and LAG-3

US11939380B2 · kind B2 · utility

0Cited by
7References
16Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 5, 2018
Grant dateMar 26, 2024
Priority date
Expiry dateMay 26, 2040

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.